Page - (000399) - in Biomedical Chemistry: Current Trends and Developments

Cruz, L. J., Rosalia, R. A., Kleinovink, J. W., et al. (2014). Targeting nanoparticles to cd40, dec-205 or cd11c molecules on dendritic cells for efficient cd8 t cell response: A comparative study. Journal of Controlled Release, 192C, 209-218. Cruz, L. J., Tacken, P. J., Fokkink, R., et al. (2010). Targeted plga nano- but not microparticles specifically deliver antigen to human dendritic cells via dc-sign in vitro. Journal of Controlled Release, 144(2), 118-126. Cubas, R., Zhang, S., Kwon, S., et al. (2009). Virus-like particle (vlp) lymphatic trafficking and immune response generation after immunization by different routes. Journal of Immunotherapy, 32(2), 118-128. Danhier, F., Feron, O., Preat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135-146. Danquah, M. K., Zhang, X. A., Mahato, R. I. (2011). Extravasation of polymeric nanomedicines across tumor vasculature. Advanced Drug Delivery Reviews, 63(8), 623-639. Davis, I. D., Chen, W., Jackson, H., et al. (2004). Recombinant ny-eso-1 protein with iscomatrix adjuvant induces broad integrated antibody and cd4(+) and cd8(+) t cell responses in humans. Proceedings of the National Academy of Sciences, 101(29), 10697-10702. Davis, M. E., Chen, Z., Shin, D. M. (2008). Nanoparticle therapeutics: An emerging treatment modality for cancer. Nature Reviews Drug Discovery, 7(9), 771-782. Deng, Z. J., Morton, S. W., Ben-Akiva, E., et al. (2013). Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and sirna for potential triple-negative breast cancer treatment. ACS Nano, 7(11), 9571-9584. Devy, L., Huang, L., Naa, L., et al. (2009). Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Research, 69(4), 1517-1526. Diwan, M., Elamanchili, P., Cao, M., et al. (2004). Dose sparing of cpg oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Current Drug Delivery, 1(4), 405-412. Doane, T., Burda, C. (2013). Nanoparticle mediated non-covalent drug delivery. Advanced Drug Delivery Reviews, 65(5), 607-621. Dobrovolskaia, M. A., Patri, A. K., Simak, J., et al. (2012). Nanoparticle size and surface charge determine effects of pamam dendrimers on human platelets in vitro. Molecular Pharmceutics, 9(3), 382-393. Dong, X., Mumper, R. J. (2010). Nanomedicinal strategies to treat multidrug-resistant tumors: Current progress. Nanomedicine (Lond), 5(4), 597-615. Dreher, M. R., Liu, W., Michelich, C. R., et al. (2006). Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. Journal of National Cancer Institute, 98(5), 335-344. Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., et al. (2007). Differential antigen processing by dendritic cell subsets in vivo. Science, 315(5808), 107-111. Egilmez, N. K., Harden, J. L., Rowswell-Turner, R. B. (2012). Chemoimmunotherapy as long-term maintenance therapy for cancer. Oncoimmunology, 1(4), 563-565. Elzoghby, A. O., Samy, W. M., Elgindy, N. A. (2012). Albumin-based nanoparticles as potential controlled release drug delivery systems. Journal of Controlled Release, 157(2), 168-182. Erogbogbo, F., Yong, K.-T., Roy, I., et al. (2010). In vivo targeted cancer imaging, sentinel lymph node mapping and multi-channel imaging with biocompatible silicon nanocrystals. ACS